Abstract bekijken

Deze abstract is toegekend aan sessies
Type presentatieE-poster
TitelEfficiency and safety of Rho Kinase inhibitors and Beta-blockers in the treament of primary open angle glaucoma after 3 month: a systematic review with meta-analysis of randomized controlled trials
DoelWe assembled scientific evidence comparing the efficacy and safety of Rho Kinase inhibitors (Rhoki) and β-blockers (β-β) in the treatment of open angle glaucoma after 3 months through systematic review and meta-analysis (meta-A) of randomized controlled trials (RCT).
MethodesLiterature search was performed using PubMed, EMBASE and Cochrane Library. Titles, abstracts then full texts were assessed according to eligibility criteria. The references that met the eligibility criteria were included in this study and data extraction was performed. A risk of bias analysis using the ROB-2 tool, heterogeneity analysis using the I2 statistic and a Meta-A with random effect model were performed. The effect size was estimated using the Cohen’s d and a funnel plot was generated to assess publication bias.
ResultatenAmong 251 articles found, three met our eligibility criteria. Methodology of the studies was homogeneous amongst the RCTs but there was an important heterogeneity among data (I squared = 92-93%; p< 0,001). ROB 2-tools suggest that all studies had a low risk of bias. The Meta-A showed statistically better efficacy of β-β resulting in an IOP reduction mean difference of 1.73 (1.19-2.27) at 8 a.m., 0.66 (0.19-1.15) at 10 a.m. and 0.49 (0.001-0.98) at 4 p.m. compared to Rhoki. The adverse effects of Rhoki were essentially topical, whereas β-β mainly caused systemic side-effects.
Conclusie This Meta-A showed a statistically significant superiority of β-β in reducing IOP, but this difference was not clinically relevant. Rhoki have a better safety profile.
BelangenverstrengelingNee
Auteur 1
NaamNANA WANDJI
InitialenB
InstituutUniversité Libre de Bruxelles
StadBruxelles
Auteur 2
NaamEhongo
InitialenA
InstituutHopital Erasme
StadBruxelles
Auteur 3
NaamBacq
InitialenN
InstituutUniversité Libre de Bruxelles
StadBruxelles
Auteur 4
NaamCastetbon
InitialenK
InstituutEcole de Santé Publique, Université Libre de Bruxelles
StadBruxelles
top ^